The SKYLARK Study, conducted by The Feinstein Institutes for Medical Research at Northwell Health, has shown promising results in treating postpartum depression (PPD). Led by Dr. Kristina M. Deligiannidis, the trial evaluated the efficacy of an investigational oral neuroactive steroid, zuranolone (50mg). The findings suggest zuranolone could become the first oral, at-home therapy approved by the FDA for PPD. The study included…
